By Sophia Dourou (July 27, 2022, 6:56 PM BST) – – A workmanship gatherer asked a requests court Wednesday to resuscitate English procedures over...

The current DeFi market is bearish as most of the tokens are priced low compared to previous months. A bear market can be caused by a variety of events, including bursting market bubbles, a poor or lagging or sluggish economy, wars, geopolitical crises, pandemics, and significant paradigm shifts in the economy, such as changing to an internet economy. Another reason can be the isolation between NFTs and DeFi space. Let’s see how NFTs can help revitalize the bearish DeFi cycle. Isolation between NFTs and the DeFi space Looking back, we can see that NFTs and DeFi protocols have worked separately in the past. However, the current bearish moves in the Defi market may be corrected by the widespread adoption of NFTs.  This is because NFTs have the capacity to assign value to nearly any object. DeFi, on the other hand, aids in the unlocking of a certain asset’s worth. When combined together, they can balance each others’ strengths and weaknesses and enhance their capabilities. Application of NFTs to the DeFi world NFTs help revolutionize the DeFi world because of the following reasons Allow for customizable and exact roles for the community members involved such as ‘avatars’ in the Metaverse games and ‘validators’ for any DeFi protocol/blockchain like Cardano. Make a distinction between the cost of government authority and the cost of native tokens. It’s possible to make DeFi a gamification land. Protocols that can fine-tune scarcity and utility-based value. Solves the illiquidity issue with veTokens The intersection of NFTs and DeFi This section will cover a few cases where the intersection of NFTs and DeFi looks promising- Uniswap v3: The only way to introduce concentrated liquidity into Uniswap v3 was to tokenize distinct LP positions. This innovative adjustment resulted in more use, resulting in higher revenues for LPs. Curve Finance- Solidly Exchange: veCRV’s Curve Finance problem was solved by Solidly exchange. Solidly enabled the lock of tokens for ve governance tokens to be tokenized, allowing for a single lock position and several lock positions with different time durations. BinaryDAO.finance: BinaryDAO.finance, a yield DAO, reinvented APR boosting by releasing a collection of 2,500 NFTs with a 25% APR for stakers. In comparison to the status quo of depending on physical locks, the release earned revenue for bootstrapping liquidity and making APR increases liquid. Nacho Finance: Nacho Finance, an algorithmic stable coin technology, is expanding its ecosystem to include a fun and engaging game. Their Luchador NFTs will allow gambling on NFT bouts and reinforce the peg by acting as a black hole for their token’s upgrades. $NACHO Final thoughts UniSwap v3 and Solidly, for example, are very different from NFT assets with defined amounts that are distributed, such as BinaryDAO and Nacho Finance. Both protocols, however, have one thing in common: they both aim to improve the protocol user’s experience. The construction of Defi protocols is significantly influenced by the techniques employed by UniSwap v3 and Solidly. However, the innovation fostered by NFT assets and the related value addition should not be underestimated. Whether you like it or not, widespread integration between DeFi-NFTs is coming.

The post Is it possible for NFTs to revive the present bearish DeFi cycle? appeared first on Cryptoknowmics-Crypto News and Media Platform.

Yoon Suk-Yeol, a conservative presidential contender, has officially been elected as the new president of South Korea. According to news reports, Yoon of the People Power Party defeated his politically progressive opponent, Lee Jae-Myung, by less than 1%. In South Korea, cryptocurrency dominated the election discourse, with both candidates launching NFTs connected to their campaigns.…

The post South Korea Has A New President – And He Likes Crypto appeared first on Bitcoin News Miner.

HONG KONG, Mar 9, 2022 - (ACN Newswire) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group's Chairman, Executive Director and Chief Executive Officer Mr. Tang Chi Fai ("Mr. Tang") acquired a total 1,000,000 shares of the Company on the market for an aggregate consideration of approximately HK$ 7.246 million at an average price of HK$7.2465 per Share. Prior to this transaction, Mr. Tang had already increased shareholdings 3 times this year with a total of 1.15 million increased shares and the average price was $9.194, $8.49 & $8.18 per share. After the transaction, Mr. Tang is interested in an aggregate of 721,927,610 Shares and his equity stake in the Group increased from 61.18% to 61.26%

In the past year, EC Healthcare has actively integrated the healthcare market through organic growth and acquisitions to further consolidate leading market position. As the epidemic has raged on in Hong Kong now, the Group also actively provides anti-epidemic medical services to the public through its general outpatient clinics, specialist clinics, health check centers, vaccine centers and laboratory centers. Looking forward, the Group remain confident for the long-term strong business growth momentum and will keep investing in IT, brand and service to provide better services to the public.

About EC Healthcare
EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.

The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre UMH DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL, NEW MEDICAL CENTER and Prime Medical Centres, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories, a professional hair care center HAIR FOREST, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.

*According to independent research conducted by Frost and Sullivan in terms of revenue in 2019 and 2020

For further information, please contact:
iPR Ogilvy Limited
Callis Lau / Lorraine Luk / Charmaine Ip
Tel: (852) 2136 6952 / 2169 0467 / 3920 7649
Fax: (852) 3170 6606
Email: [email protected]


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comEC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group's Chairman

HONG KONG, Mar 9, 2022 - (ACN Newswire) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce, to reduce the infection risk from going out for medical consultation, the Group launch Tele-Medicine service under EC Healthcare Medical Centre, AI MEDICAL, PRIMEcare, chiropractor and traditional medicine services under NYMG. The Group's professional medical team will fully be devoted to providing services to the public. The Group formed a dedicated team that can provide 500 session telemedicine services per day at the first phase and will continue to scale up to match the demand from our clients.

Please book via EC Healthcare online platform: https://ectelemedicine.echealthcare.com/

If you have any enquiry, please contact Customer Service Hotline: 2152 8503

The Tele-Medicine mainly provides common diseases consultation and chronic disease follow-up consultation. The teleconsultation can cover flu, diarrhea, rash, sinusitis, red eye, indigestion, diabetes, hypertension and hyperlipidemia. After the teleconsultation, the Group will also arrange a drug delivery service within four hours*. This service helps citizens to manage health conditions at home.

Apart from teleconsultation, the Group's service centers located in each district include general outpatient clinics, specialist clinics, health check centers, vaccine centers and laboratory centers still commence usual operation and provide vaccine, pre-vaccine body check, PCR test and antibody test. The Group is devoted to being the public's health guardian, serving the community, and contributing to the anti-epidemic work.

*Drug delivery service arrive time is subject to prevailing conditions

About EC Healthcare
EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.

The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre UMH DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL, NEW MEDICAL CENTER and Prime Medical Centres, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories, a professional hair care center HAIR FOREST, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.

*According to independent research conducted by Frost and Sullivan in terms of revenue in 2019 and 2020


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comEC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce, to reduce the infection risk from going out for medical consultation

HONG KONG, Mar 7, 2022 - (ACN Newswire) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Company has been included as an eligible stock of Shenzhen-Hong Kong Stock Connect, with effect from March 7, 2022, pursuant to the Announcement on Adjustment of the Stock List of Hong Kong Stock Connect issued by the Shenzhen Stock Exchange on March 7, 2022. Mainland investors can directly trade the Company's stock after the Company is included as an eligible stock of the Shenzhen - Hong Kong stock connect.

The Company believes the inclusion of the shares of the Company in the trading mechanism of Shenzhen-Hong Kong Stock Connect demonstrates market recognition of the Company's investment value and growth prospects. The Company believes the inclusion will allow the Company to access a broader investor base in Mainland China and further expand the shareholder base of the Company, increase the trading liquidity of the shares of the Company, support the sustainable growth of the Company in the long term.

The Company would like to thank the shareholders and investors of the Company for their continued support. The Company will continue to strive to develop its business to consolidate the healthcare market and create value for its shareholders.

About EC Healthcare
EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.

The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre SPINE Central, New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre UMH DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL and NEW MEDICAL CENTER, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories, a professional hair care center HAIR FOREST, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.

*According to independent research conducted by Frost and Sullivan in terms of revenue in 2019 and 2020

For further information, please contact:
iPR Ogilvy Limited
Callis Lau / Lorraine Luk / Charmaine Ip
Tel: (852) 2136 6952 / 2169 0467 / 3920 7649
Fax: (852) 3170 6606
Email: [email protected]



Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comEC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Company has been included as an eligible stock of Shenzhen-Hong Kong Stock Connect

HONG KONG, Feb 28, 2022 - (ACN Newswire) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group's Chairman, Executive Director and Chief Executive Officer Mr. Tang Chi Fai further increases the shareholdings post the equity stake increase announced on January 17. Mr. Tang acquired a total 605,000 shares of the Company on the market for an aggregate consideration of approximately HK$ 4.96 million. On January 21, Mr. Tang acquired a total of 62,000 shares at an average price of approximately HK$8.49 per share and acquired a total of 543,000 shares at an average price of approximately HK$8.18 on January 22. After the transaction, Mr. Tang's equity stake in the Group increased to 60.39%

In the past year, EC Healthcare has actively integrated the healthcare market through organic growth and acquisitions to further consolidate leading market position. As the epidemic has raged on in Hong Kong now, the Group also actively provides anti-epidemic medical services to the public through its general outpatient clinics, specialist clinics, health check centers, vaccine centers and laboratory centers. Looking forward, the Group remain confident for the long-term strong business growth momentum and will keep investing in IT, brand and service to provide better services to the public."

About EC Healthcare
EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.

The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre UMH DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL, NEW MEDICAL CENTER and Prime Medical Centres, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories, a professional hair care center HAIR FOREST, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.

*According to independent research conducted by Frost and Sullivan in terms of revenue in 2019 and 2020


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comEC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group's Chairman, Executive Director and Chief Executive Officer Mr. Tang Chi Fai further increases the shareholdings post the equity stake increase announced on January 17.

Find out where you can locate Drake's Map in Fortnite Chapter 3 Season 1 and how to locate the buried…

The post Fortnite Drake’s Map: Where to Find & How to Use appeared first on Esports News Network | ESTNN.

HONG KONG, Feb 18, 2022 - (ACN Newswire) - EC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group has been selected and will be included as a constituent stock of the following index series by Hang Seng Indexes Company Limited, with effect from 7 March 2022:

(1) Hang Seng Composite SmallCap Index
(2) Hang Seng Small Cap (Investable) Index
(3) Hang Seng Healthcare Index
(4) Hang Seng Stock Connect Hong Kong Index
(5) Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index
(6) Hang Seng Stock Connect Hong Kong SmallCap Index
(7) Hang Seng SCHK HK Companies Index
(8) Hang Seng SCHK ex-AH Companies Index

The Hang Seng Composite Index ("HSCI") serving as a comprehensive Hong Kong market. HSCI covers the top 95th percentile of the total market capitalisation of companies listed on the Main Board of the Stock Exchange of Hong Kong ("SEHK"). Adopting the freefloat-adjusted market capitalisation methodology, HSCI can be used as a basis for index funds, mutual funds as well as performance benchmarks. The HSCI inclusion also implies that the Company are eligible stocks for Stock Connect, which is an important scheme for mutual stock market access between the Mainland and Hong Kong. As EC Healthcare becomes eligible stocks for Stock Connect, the mainland investors can directly trade the Company's stock. are able to deal in the Company's shares directly. This demonstrates the market's recognition of the Company's long-term value and growth potential.

Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, "The inclusion of EC Healthcare in the Hang Seng Composite Index demonstrates the capital market's recognition of the Group's growth potential. As a constituent of the Index and a stock eligible for the Hong Kong Stock Connect, EC Healthcare will be able to further expand its shareholder base and trading liquidity, resulting in realization of the value of investment in the Company and enhancement of the Company's reputation in the capital market. Looking ahead, the Group will continue to refine its business capabilities and further build up the enclosed ecosystem through organic growth as well as mergers and acquisition. This will enable us to provide health management services to more people, create greater value for our clients, thereby creating greater returns for shareholders and leading the industry in upgrading and development."

About EC Healthcare
EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the MSCI Small Cap Index and the Hang Seng Composite Index.

The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre SPINE Central, New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre UMH DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL and NEW MEDICAL CENTER, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories, a professional hair care center HAIR FOREST, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.

*According to independent research conducted by Frost and Sullivan in terms of revenue in 2019 and 2020

For further information, please contact:
iPR Ogilvy Limited
Callis Lau / Lorraine Luk / Charmaine Ip
Tel: (852) 2136 6952 / 2169 0467 / 3920 7649
Fax: (852) 3170 6606
Email: [email protected]



Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comEC Healthcare (the "Company", which together with its subsidiaries is referred to as the "Group", SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group has been selected and will be included as a constituent stock of the following index series by Hang Seng Indexes Company Limited, with effect from 7 March 2022

Three years ago, a cryptocurrency game got so popular that players brought the Ethereum Network to its knees just to win. Today, that game, Fomo3D is back, but instead of suffering the high transaction costs that plagued its predecessor, it--and its token counterpart, P3D--utilize the Binance Smart Chain to make the game more accessible to ordinary players. 

At the moment, the game has only been running since November 11th, but the prize pot has already surpassed 481 BNB, or $275,000 USD. The game's mechanics are somewhat simple: players buy keys to contribute to the pot, the pot is attached to a 24 hour clock that is continuously counting down, whoever buys the last key collects the jackpot. Every time a key is bought, 30 seconds are added to the clock and the price of the next key increases slightly. However, even if somebody else wins the jackpot, keyholders and token-stakers still collect passive income through dividends from key purchases. Furthermore, when the clock runs out, those still holding tokens receive portions of the jackpot proportional to their share of tokens. 

What makes the token itself even more enticing is its usage of a deflationary mechanism, every time a holder sells their share of coins, 10% are automatically burned. Since the launch of the P3D token, over 15% of its original billion coins have already been burned, which is great for investors. While other coins such as the extremely popular Shiba Inu token excitedly talk about their coin burning down until the value is .01 USD within five years, holders of P3D may very well see that sort of price point within a few months, if not weeks.

“We had a lot of burn even before the game launched,” said developer Smokey Nagata, “I think a lot of people saw some of the hype around the launch and thought it would be a good opportunity to make a quick profit, but I'm sure a lot of them are kicking themselves right now.”

However, it is exactly this kind of hit-and-run approach to cryptocurrency that made “Smokey” want to revive the game for 2021. 

“It's been a big year for cryptocurrency,” explained “Smokey,” “investment news channels talk about NFTs and Dogecoin with the same seriousness as they do the DOW and NASDAQ; but it's still the Wild West. People talk about Fomo3D as if it was just a game, but it was so much more than that. The overall project, the Proof of Weak Hands (PoWH) was originally designed as a commentary about the state of the cryptocurrency market back in 2018: it was mocking the jargony buzzwords and slapdash whitepapers that riddled the landscape back then. Ironically enough, it's probably more relevant today than even when it was originally launched.”

Keys for the lottery are available for purchase on the FOMO3D website and can be purchased using Metamask, TrustWallet, and WalletConnect.  As of now, the P3D token is exclusively available on PancakeSwap and Rubic Exchange, but the developers have eyes on expansion, if not outright global domination. 

“What do I think will be the endgame?” “Smokey” could only speculate, “maybe a few crypto billionaires will be left to fight it out, maybe nations will band together to win it all, or maybe the entire network will crash like in 2018. All I know is it's gonna be a bloodbath.”

To connect with the team behind Fomo3D and P3D, follow their Twitter, or join them on Telegram.
To learn more in-depth about the game's mechanics, check out the FOMO3D Wiki.

  The battle royale genre has been dominating the gaming world lately and sadly, the beautifully creative SpellBreak hasn’t got the attention it deserves.  Is Spellbreak worth buying? Well, the class-based third-person shooter is free-to-play, so you won’t have to spend a dime to play. But is it worth playing?  That’s what we’ll find out […]

The post Review of SpellBreak in 2021 🧙 Is It Still Worth It? appeared first on Gamer One.